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Endothelin-1 (ET-1) has been implicated in the pathogenesis of Chronic Obstructive Pulmonary
Disease (COPD) for establishing an inflammatory loop in the respiratory mucosa that could
become independent from the initial irritant factor. Common causes of COPD exacerbations
are associated with elevated ET-1 sputum concentrations. Genetic variants of the ET-1 gene,
that lead to elevated ET-1 peptide levels, have not been investigated in COPD.
We performed a case control, genetic study to assess possible associations of two polymor-
phisms of the ET-1 gene, an adenine insertion (þ134 insA/delA) and a guanine to thymine
transversion (G198T) with the COPD phenotype and disease severity.
The genotypes of 209 subjects, 107 COPD smokers (patients) and 102 non-COPD smokers
(controls) were examined. Statistical analysis revealed that the 3A/4A and 4A/4A genotypes
were more common (P< 0.01) in patients. Moreover, a protective effect against COPD of the
TT genotype (G198T) was exhibited. COPD smokers were carrying more frequently the GG
genotype and less frequently the TT genotype (PZ 0.047). Diplotypic analysis revealed that
subjects carrying the 3A3A;TT genotype had a lower risk of COPD development (PZ 0.027).of Pulmonology, University Hospital of Rio, 26500, Patras, Greece. Tel./fax: þ30 2610999523.
mail.com (K. Spiropoulos).
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Endothelin-1 gene polymorphisms in COPD 115Within the COPD patient group carriers of the GT genotype had more often mild or moderate
COPD compared to patients carrying the GG genotype (PZ 0.004). Haplotypic distribution re-
vealed that carriers of the 4A:T and 4A:G haplotypes were in increased risk of COPD develop-
ment. Additionally, patients with the 3A:G haplotype were in increased risk of developing
severe COPD, whereas patients with the 3A:T and 4A:T had most probably mildemoderate COPD.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a wide-
spread multifactorial disease with a heterogeneous patho-
genesis. Cigarette smoking is the major risk factor, however
only 10e20% of smokers develop symptomatic COPD. This,
along with several other lines of evidence, such as, familial
clustering, twin studies, accelerated decline of Forced
Expiratory Volume in 1 s (FEV1), suggest complex genetic
components for the disease.1 A-1 antitrypsin deficiency is
the only proven genetic risk factor for COPD development,
while numerous association studies examine other candi-
date gene loci to establish involvement in COPD. Failure to
replicate some of these studies makes them controversial.2
COPD is the fourth leading cause of morbidity and mortality,
expected to rise to the third position, by the year 2020.3
Recent studies revealed that in COPD, response to
inflammation, especially in small airways, is characterized
by an amplification that does not cease when cigarette
smoking is withdrawn, thus becoming independent of the
causal mechanism.4,5 It has been reported that high levels of
Endothelin-1 (ET-1) in BronchoAlveolar Lavage (BAL) are
implicated in COPD pathogenesis, via their involvement in
the inflammatory cycle.6,7 ET-1 preserves inflammation in
the respiratory mucosa independently of the initial inflam-
matory stimulus, therefore establishing an autocrinee
paracrine loop.8e11
Endothelin-1 is an important regulator of inflammation
in the lung milieu and is produced by vascular endothelial
cells, bronchial epithelial cells, pulmonary monocytes,
polymorphonuclear leucocytes and fibroblasts.12,13
An explanation of the COPD pathogenesis and pulmonary
hypertension development proposes apoptosis of alveolar
and epithelial cells followed by the failure of vascular
epithelial repair as a cause of emphysema. Smoke exposure
provokes many harmful vascular effects, such as increasing
the expression of vasoconstrictor and mitogenic factors, like
ET-1. The ‘‘earliest’’ pathology of the lungs of smokers is the
development of intimal thickening of pulmonary arteries,
the severity of which is correlated with the daily number of
cigarettes smoked. Therefore, the autocrine actions of ET-1
(pro-inflammatory, vasoconstrictor and mitogenic) may be
involved even in early lung remodeling due to smoking, and
also could contribute to disease severity and pulmonary
hypertension in COPD, since failure of alveolar and epithelial
repair is a characteristic of advanced disease.14
The human ET-1 gene is located on chromosome 6p and
consists of 5 short exons and 4 introns. Its product is
synthesized as a precursor molecule, the preproendothelin
that is hydrolyzed by many converting enzymes, to the
mature active 21 amino acid ET-1 peptide. Lung displays
the highest levels of ET-1 production and activity among allother organs maintained by activation of gene transcrip-
tion, since precursor or active ET-1 peptides are not stored
within cells. Lung is also the main site of ET-1 clearance
from circulation. ET-1 acts in the lung tissue as an
autocrineeparacrine signal on ET-A and ET-B receptors that
mediate its activities locally, while a small portion of the
total ET-1 production is secreted in the blood, where its
half life time is 4e7 min.15
Single-nucleotide polymorphisms (SNPs) of ET-1 gene
have been associated with variations in ET-1 levels.16,17 An
adenine insertion SNP is located 138 bp downstream of the
transcription start site in the 50-UTR (Untranslated Region),
in exon 1 (þ134 insA/delA).16 Transfection studies using
reporter constructs showed that this insertion could
account for elevated ET-1 levels, probably due to increased
mRNA stability, rather than translation efficacy. It is
possible that preproET-1 mRNA forms different stem-loops
of 50-UTR transcripts and that adenine insertion changes
the free energy, number and secondary structure of stem-
loops, thus affecting transcriptional stability.16
A single-nucleotide polymorphism in exon 5, which
replaces guanine by thymine (G198T, GeT transversion
Codon 198) leading to substitution of a lysine by asparagine
(Lys198Asn), has also been associated with elevated ET-1
blood levels.17 As far as polarity and charge are concerned
lysine and asparagine belong to different amino acid
groups, therefore substitution of lysine by asparagine may
alter the tertiary structure of the protein and consequently
its function (stability and proteineprotein interaction).
Since ET-1 is involved in the maintenance of inflamma-
tion in the lung of COPD patients,6,7 it is plausible that
polymorphisms of the ET-1 gene, which affect availability
and function of its molecule, may modulate the risk of
COPD development. To test this hypothesis, we conducted
a case-control study to examine the differences in the
frequency of these SNPs among COPD smokers (patients)
and non-COPD smokers (controls) as well as their effects on
lung function in a Caucasian Greek population.Methods
Subjects
The study cohort consisted of 209 subjects, including 107
consecutive COPD smokers, defined as patients, that were
recruited from the outpatient pulmonary clinic of Patras’
University Hospital from March 2005 to January 2007 and
102 non-COPD smokers, defined as controls, randomly
selected from the general population (people visiting the
hospital for a health check-up and community volunteers)
and overall matched to the group of patients for age,
116 F. Sampsonas et al.smoking habit (pack-years), Body Mass Index (BMI, kg/m2)
and sex. All participants were current or ex-smokers with
a history of at least 20 pack years of smoking and were
subjected to spirometry, including a bronchodilator test,
using a computerized system, by the same technician
(Pulmolab 435 Morgan Data Acquisition System 401, USA)
according to established guidelines.18 Patients with poorly
reversible airflow limitation associated with bronchiectasis,
cystic fibrosis and fibrosis due to tuberculosis were
excluded. The cumulative cigarette dose (pack-year) was
calculated using the following formula: pack-yearZ (packs
per day) (years of smoking).
Regarding the Forced Expiratory Volume in 1 s (FEV1),
the higher of the values obtained in two technically satis-
factory tracings was taken. Additionally, FEV1 reversibility
after inhalation of 200 mg salbutamol was <12% of pre-
bronchodilator FEV1. A flow volume loop was also obtained
for all subjects and the Forced Expiratory Flow of the 25%,
50%, 75% of the Forced Vital Capacity (FEF-25, -50, -75,
respectively) and the average expiratory flow over the
middle half of the FVC (FEF 25e75) were recorded.
Patients satisfied the criteria proposed by the Global
Initiative for Chronic Obstructive Pulmonary Disease
[GOLD]. GOLD scales of severity were used to verify stages
of the disease.3 Non-COPD smokers (control group) had
normal spirometry and no respiratory symptoms. All
subjects had no major comorbidities such as heart failure,
renal dysfunction, cancer or severe hypertension.
The study was approved by the University of Patras
Ethics Committee and the Scientific Committee of the
University Hospital of Patras, and all subjects signed
a patient’s consent form.
Blood collection and genotyping
DNA was isolated from 3 ml of whole blood, using QIAamp
DNA blood mini kit (QIAGEN). The ET-1 gene poly-
morphisms þ134 insA/delA in the 5’untranslated region
and G198T, in exon 5, were genotyped in 107 patients and
102 controls. Genotyping was performed with real time
PCR using the MX3000p (Stratagene, La Jolla, CA, USA).
The primers and MGB Taqman probes used for the G198T
polymorphism were as previously reported.19 For the þ134
insA/delA polymorphism the primers 50-TTC TCT CCT GGC
AGG-30 and 50-ATC TCA AAG CGA TCC TTC-30 were used in
conjunction with the LNA (Locked Nucleic Acid) Taqman
probes 50-(6-Fam) AGþ TGCCþ CþTþ Tþ TAACGG
(BHQ1)-30 (for 3A allele) and 50-(Hex) AGT GCCþ Cþ
TþTþ Tþ TAAþ CGþGG (BHQ1)-30 (for 4A), where
a ‘‘þ’’ before the base indicates an LNA base. Primers
were synthesized by Metabion International (Martinsried,
Germany), MGB probes by Applied Biosystems (Foster City,
CA, USA) and LNA probes by SigmaeProligo (The Wood-
lands, TX, USA). Reactions were performed using Brilliant
QPCR Master Mix (Stratagene).
Statistical analysis and methodology
The normality of the numerical parameters was tested
using the KolmogoroveSmirnov test. Comparisons of
demographic data between groups were performed withthe Chi-squared analysis or unpaired t-test, as appropriate.
Logistic regression analysis was used to quantify the asso-
ciation between the genotypes and COPD, since it is
applicable for broader range of research situations,
compared to discriminated analysis. Chi-squared analysis
was used for categorical variables. Correlations of spiro-
metric values (FEV1, FEF 25e75) with genotypes were
tested with one-way ANOVA for normally distributed vari-
ables (within the patient and control groups) and Kruskale
Wallis and ManneWhitney tests for non-normally distrib-
uted variables. For multiple comparisons, the ANOVA tests
were followed by a post hoc Bonferroni test. P-values lower
than 0.05 were considered significant. Statistical analysis
was performed using SPSS statistical package (SPSS, Release
14.0.1, Chicago, IL, USA). Haplotypic analysis was per-
formed using the FAMHAP software program, based on the
Monte-Carlo simulations. The haplotype frequencies
computed by the program are maximum-likelihood esti-
mates (MLEs), obtained with the expectation-maximization
(EM) algorithm (http://famhap.meb.uni-bonn.de).
Results
Characterization of subjects
The baseline characteristics of the 209 subjects, repre-
senting a homogeneous Greek population, are listed in
Table 1. The parameters of FEV1 and FEV1/FVC were
significantly decreased in the COPD patients compared to
controls. The group of COPD patients consisted of 99 active
and 8 ex-smokers, whereas the control group consisted of
95 active and 7 ex-smokers.
Genotypes of the control group were found by Pearson’s
goodness-of-fit Chi-square test to be in HardyeWeinberg
equilibrium (PZ 0.21 for the þ138 3A/4A SNP and PZ 0.17
for the G198T).
Table 2 summarizes the distribution of genotypes (of the
adenine insertion/deletion þ134 insA/delA) and G198T
SNPs in patients and controls. Statistical analysis revealed
that the frequencies of the þ134ins/delA genotype was
statistically significantly different between patients and
controls (PZ 0.017, c2Z 8.178). Subjects carrying the
3A4A and the 4A4A genotypes had increased risk of COPD
development (ORZ 1.427, 95%CIZ 1.089e1.871 and
ORZ 2.622, 95%CIZ 0.842e8.165, respectively, Reference
genotype:3A3A).
Regarding the G198T SNP, 69 out of 107 COPD smokers
carried the GG genotype, 34 the GT genotype and 4 the TT
genotype. Among controls, 53 out of 102 subjects carried
the GG genotype, 37 the GT genotype and 12 the TT
genotype. The distribution of these genotype was signifi-
cantly different between patients and controls (PZ 0.047,
c2Z 6.109) (Table 2). Statistical analysis revealed that
subjects carrying the GG genotype were in increased risk of
COPD development (ORZ 1.241, 95%CIZ 0.982e1.568,
Reference genotype: GT/TT) (Table 2).
Distribution of the 3A, 4A alleles revealed that the 3A
allele is more common in controls, whereas the 4A allele
was significantly more common in patients (c2Z 6.42,
PZ 0.011). Regarding the 198G, T alleles statistical analysis
revealed that the G allele was more common in patients,
Table 1 Baseline demographic characteristics of COPD patients and controls.
COPD patients (nZ 107) Controls (nZ 102) P value
Smoking (pack years) 59,18 (26.9) 59,5 (32.7) NS
Age (years) 61.07 (9.7) 58.96 (9.4) NS
BMI 28.22 (5.9) 28.37 (5.4) NS
FEV1(%Predicted)
{ 50.36 (18.4) 98.71 (10.8) <0.0001
FEV1/FVC(%Predicted) 56.91 (10.1) 80.73 (5.7) <0.0001
SEX (M/F) 86/21 80/22 NS
Current/ex-smokers 99/8 95/7 NS
GOLD status I:8, II:42, III:43, IV:14
Education Primary (34%) Primary (32%)
Secondary (57%) Secondary (56%)
Tertiary (9%) Tertiary (12%)
{Post bronchodilation FEV1; NS: non significant, M: Male, F: Female, BMI: Body mass Index.
Endothelin-1 gene polymorphisms in COPD 117whereas the T allele was more common in controls
(c2Z 5.94, PZ 0.014).
Within the total study cohort, patients carrying the 3A3A
genotype had higher FEV1 and FEF 25e75 values compared to
3A4A (P< 0.05-Bonferoni analysis for FEV1 and FEF 25e75)
and 4A4A genotypes (P< 0.05 for FEV1), whereas subjects
carrying the TT genotype had higher FEV1 and FEF 25e75
values compared to those carrying the GG genotype
(P< 0.005).
Within the COPD group, carriers of the TT genotype
(G198T SNP) demonstrated statistically significant higher
FEV1 (PZ 0.014-Bonferoni analysis) and FEF 25e75
(PZ 0.006-Bonferoni analysis) spirometric values (Fig. 1a
and b respectively). Statistical analysis revealed that
carriers of the GT genotype had more often mild or
moderate disease (GOLD IeII) (PZ 0.004, ORZ 3.562,
95%CIZ 1.505e8.430). Moreover, carriers of at least one
T allele (GT or TT genotypes) had most probably GOLD IeII
compared to patients carrying the GG genotype (PZ 0.004,
ORZ 3.385, 95%CIZ 1.475e7.768). No significant correla-
tions of the þ134 SNP, in patient group, with disease
severity and spirometric values were noted (Fig. 2a,b).
Analysis of both genotypes in combination revealed that
carriers of the 3A3A; GG genotype were less likely to
develop mild-moderate disease (PZ 0.006, ORZ 0.164,
95%CIZ 0.044e0.602).Table 2 Genotype distribution in patients and controls.
Polymorphism þ134insA/delA Genotype distribution
Controls Patients
n (%) n (%)
3A3A 55 (54) 37 (35)
3A4A 43 (42) 62 (58)
4A4A 4 (4) 8 (7)
G198T Controls Patients
GG 53 (52) 69 (64)
GT 37 (36) 34 (32)
TT 12 (12) 4 (4)
GT/TT 49 (48) 38 (36)
NS: non significant, CI: confidence interval, OR: odds ratio.All theoretically possible haplotypesexist in theexamined
population. Haplotypic distribution of genotypes was
remarkably different among patients and controls (Global
PZ 0.0011) (Table 3a), revealing that subjects with 4A:Tand
4A:G haplotypeswere in increased risk of COPDdevelopment
(ORZ 1.725, 95%CIZ 0.4209e7.0828, and ORZ 1.589,
95%CIZ 0.844e3.0064, respectively) while subjects with
3A:T haplotype had a lower risk in COPD development
(ORZ 0.442, 95%CIZ 0.219e0.9212), indicating the impor-
tant role of the 4A allele in disease development (Table 3a).
Additionally, haplotypic distribution was also diverse
among patients with less (GOLD IeII) or more severe (GOLD
IIIeIV) disease (Global PZ 0.0165) (Table 3b). Subjects with
the 3A:G haplotype were in increased risk of severe COPD
development (GOLD IIIeIV) (OR:1.8162, 95%CIZ 1.0367e
3.1819), whereas subjects carrying the 3A:T and 4A:T
haplotypes had lower risk of severe COPD development
(ORZ 0.4812, 95%CIZ 0.2145e1.0793 and ORZ 0.3209,
95%CIZ 0.0744e1.3842, respectively), revealing the
significant role of G allele in the disease severity (Table 3b).Discussion
ET-1 is involved in the pathogenesis of various lung
diseases, including COPD.6,20 COPD exacerbations areP value (c2) OR 95%CI
0.017 (8.178) 1.427 1.089e1.871
2.622 0.842e8.165
P value(c2) OR 95%CI
0.047 (6.109) 1.241 0.982e1.568
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Figure 1 Comparison of FEV1 (a) and FEF 25e75 (b) values and their associations with G198T SNP (GG, GT, TT genotypes), in the
patient group.
118 F. Sampsonas et al.associated with elevated sputum ET-1 concentrations.21
Additionally the pro-inflammatory cytokines, IL-6 and IL-8,
are elevated in the airways of COPD patients both during
and in-between exacerbations.23 An interesting positive
feedback loop between ET-1 peptide and IL-6 and IL-8 has
been described in lung epithelial cells.8,22 Once the loop is
initiated, it may become independent of the original
inflammatory stimulus.4,8 Inflammation in COPD persists for
a long time, even years, after smoking cessation.24,25 Acute
smoke exposure induces the expression of the ET-1 peptide 26
which might maintain inflammation after withdrawal of
smoking.4,8
Additionally, ET-1 is an important local mediator of
inflammation in the lung. ET-1 is a powerful chemo-
attractant for various inflammatory cells, especially eosin-
ophils.24 Patients with COPD that do not currently smoke
have increased number of inflammatory cells, i.e. neutro-
phils, macrophages, and astonishingly eosinophils, in their
sputum.23 Furthermore, ET-1 promotes mucous secretion,20 
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Figure 2 Comparison of FEV1 (a) and FEF 25e75 (b) values and
genotypes), in the patient group.airway smooth muscle constriction, microvascular leakage,
vascular cell adhesion molecules27 and matrix metal-
loprotease secretion28 all of which are implicated in COPD
pathogenesis.29
It’s plausible that increased ET-1 levels due to poly-
morphisms in ET-1 gene might result in enhanced inflam-
matory response to common environmental stimuli (i.e.
cigarette smoking, viral infection) that may eventually
become independent from the initial stimuli. Recent
studies highlighted the fact that SNPs in the ET-1 gene are
implicated in the elevation of ET-1,16,19 probably due to
increased stability of the ET-1 mRNA.16 Therefore, carriers
of such genetic alterations could face an increased risk of
COPD development in response to environmental stimuli, as
a result of increased ET-1 levels, compared to non-carriers.
In the present study we focused our attention on two
biologically and probably clinically significant polymorphic
sites of the ET-1 gene. We have demonstrated that the
adenine insertion SNP is associated with the COPD0
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Table 3a Haplotypic distribution within the total study
cohort.
Haplotype Patients Controls OR 95%CI
3A:G 53 (49.6%) 49 (47.9%) 1.072 0.6147e1.8639
4A:T 6 (5.4%) 3 (3.2%) 1.725 0.4209e7.0828
3A:T 15 (14%) 28 (26.9%) 0.442 0.219e0.9212
4A:G 33 (31%) 22 (22%) 1.589 0.844e3.0064
Total 107 (100%) 107 (100%)
OR: odds ratio, 95%CI: confidence interval.
Endothelin-1 gene polymorphisms in COPD 119phenotype and lower FEV1 values and therefore the þ138
4A allele is implicated in COPD pathogenesis. It is possible
that subjects carrying at least one 4A allele create a pre-
proET-1 mRNA that forms different stem-loops of 50-UTR
transcripts and that adenine insertion changes the free
energy, number and secondary structure of stem-loops.
Further studies are needed to elucidate the mechanisms
underlying these associations. However, we tempt to
speculate that this polymorphism might result in increased
production of ET-1 in response to cigarette smoke, self-
preservation of inflammation and finally COPD develop-
ment. Haplotypic analysis revealed that the 4A:G and 4A:T
haplotypes are associated to COPD development, confirm-
ing the aforementioned data for the involvement of the 4A
allele in disease progression. Nevertheless, the 4A allele
was not related to disease severity, but may be involved in
early lung remodeling due to smoking.14
Regarding the G198T SNP, our study revealed that the TT
genotype was more prevalent among non-COPD smokers
(controls) and that the T allele was related to better lung
function tests and milder COPD. On the other hand, the
G allele, the GG genotype and the G: 3A haplotype are
related to severe (GOLD IIIeIV) COPD.
The mechanism by which the T allele seems to confer
protection against COPD development, while the G allele is
associated with disease severity is not clear. This SNP hasn’t
been studied in relation to ET-1 peptide levels in lung
tissue. Moreover, even though the G198T SNP is responsible
for an amino acid change (Lys198Asn), the position of this
SNP is not in proximity with the regulatory loci of the
transcriptional sites.30 Thus, it is rather improbable to
modulate the precursor ET-1 molecules. This does not
exclude the possibility that the SNP is in linkage disequi-
librium with the actual protecting genetic locus, since it is
in proximity with the HLA group of antigens and TNF groupTable 3b Haplotypic distribution in the patient group,
according to COPD severity.
Haplotype GOLD IeII GOLD IIIeIV OR 95%CI
3A:G 21 (41.4%) 32 (56.2%) 1.8162 1.0367e3.1819
4A:T 4 (7.4%) 1 (2.5%) 0.3209 0.0744e1.3842
3A:T 10 (19.6%) 6 (10.5%) 0.4812 0.2145e1.0793
4A:G 15 (31.6%) 18 (30.8%) 1.0370 0.5296e1.7525
Total 50 (100%) 57 (100%)
OR: odds ratio, 95%CI: confidence interval.of genes that are implicated in inflammatory process and
tissue damage. Moreover, the amino acid substitution might
decrease the activity of ET-1 (stability and protein-protein
interaction) or interfere with the cleavage of the peptide.
Lysine and asparagine belong to different amino acid groups
(with diverse polarity and charge), therefore substitution of
lysine by asparagine may alter the tertiary structure of the
protein.
Since the first reference for peptidergic activity
produced in endothelial cells31 ET-1 was put forward as
a promising molecule implicated in numerous pathogenic
pathways. Our study is, to our knowledge, the first to
associate two ET-1 polymorphisms with the COPD pheno-
type. Our results indicate that the þ138 4A/3A and G198T
SNPs are significantly involved in COPD pathogenesis and
therefore prove useful as markers for the identification of
subjects at increased risk to COPD development. Further
studies will clarify the role of these polymorphisms in COPD
development and the molecular pathways underlying their
action.
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